LGVN · Longeveron Inc.

Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines, with its primary product candidate, laromestrocel (Lomecel-B), targeting four indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, Pediatric Dilated Cardiomyopathy, and Aging-related Frailty. The company's most advanced program is the ELPIS II Phase 2b clinical trial for HLHS, which has completed enrollment with top-line results anticipated in the third quarter of 2026. The FDA has granted Rare Pediatric Disease Designation, Orphan Drug Designation, and Fast Track Designation for laromestrocel in HLHS. For Alzheimer's disease, the company received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations following positive Phase 2a results.

This S-1 registration statement covers the resale of 30,865,385 shares of Class A common stock by selling stockholders, comprising shares issued in a March 2026 private placement, shares issuable upon conversion of Series A preferred stock, and shares issuable upon exercise of placement agent warrants. The company will not receive proceeds from the resale; however, it may receive up to approximately $1.3 million if the PA Warrants are exercised for cash. The recent private placement generated approximately $15.9 million in gross proceeds at the initial closing, with a potential second closing contingent on achieving clinical and stock price milestones.

The company faces significant financial and operational challenges. An independent registered public accounting firm included an explanatory paragraph in its report on the financial statements for the year ended December 31, 2025, expressing substantial doubt about the company's ability to continue as a going concern due to working capital deficiency, stockholders' deficit, and recurring losses. The company expects its current cash and cash equivalents to fund operations into the fourth quarter of 2026. Additionally, the company is currently non-compliant with Nasdaq's $1.00 minimum bid price requirement and has been granted a second 180-day compliance period until September 21, 2026, to regain compliance. Failure to regain compliance could result in delisting, which would likely reduce liquidity and adversely affect the stock price.

Governance and capital structure present additional considerations for investors. The company has a dual-class stock structure where Class B common stock carries five votes per share compared to one vote for Class A common stock. As of April 2, 2026, three holders of Class B common stock control voting rights over approximately 21% of the combined voting power. The company also temporarily fell out of compliance with Nasdaq audit committee composition requirements following a director resignation in March 2026, though it has appointed a replacement director and plans to appoint an audit committee financial expert within the required cure period. The registration of a significant number of shares for resale by selling stockholders could create downward pressure on the stock price.